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The epidermal growth factor receptor (EGFR) and its downstream signaling pathways are involved in the development and
progression of several human tumors, including colorectal cancer. Much attention has been given to the EGFR pathway as of
lately because both EGFR and some downstream components serve as targets for anticancer therapy. In addition to playing a
critical role in targeted therapy, alterations in this pathway can have prognostic implications. The EGFR pathway and its impact
on colorectal carcinogenesis and prognosis are the emphasis of this paper. Since prognosis is tightly related to response to various
therapies, the predictive value of the components of this pathway will be brieﬂy discussed, but this is not the focus of this paper.
1.Introduction
The epidermal growth factor receptor (EGFR) and its
downstream signaling pathways regulate key cellular events
that drive the progression of many neoplasms. EGFR is
expressed in a variety of human tumors, including gliomas
and carcinomas of the lung, colon, head and neck, pancreas,
breast, ovary, bladder, and kidney. Mutations, gene ampli-
ﬁcation, and protein overexpression of various elements of
this pathway not only contribute to carcinogenesis but also
impact prognosis and provide speciﬁc targets for therapeutic
intervention. The importance of EGFR and its signaling
pathway in colorectal carcinogenesis is the topic of this
paper. Since prognosis is tightly related to response to
various therapies, the predictive value of the components
of this pathway will be discussed, but only brieﬂy. There is
another paper in this series, “Impact of KRas mutations on
management of colorectal cancer” by Sullivan and Kozuch,
which provides an in-depth review of the predictive value of
KRas and other members of the EGFR signaling pathway.
2.EGFRandthe EGFRSignalingPathway
EGFR is a 170-kDa transmembrane tyrosine kinase receptor
that belongs to the ErbB family of cell membrane receptors.
In addition to EGFR (also known as HER1 and ErbB-1),
other receptors in this family include HER2/c-neu (ErbB-2),
Her 3 (ErbB-3), and Her 4 (ErbB-4). All of these receptors
contain an extracellular ligand-binding region, a single
membrane-spanning region, and a cytoplasmic tyrosine-
kinase-containing domain.
In normal cells, the EGFR signaling cascade begins
with ligand activation of EGFR (Figure 1). Up to eleven
ligands can bind the ErbB family of receptors, including EGF
and transforming growth factoralpha [1]. Ligand binding
induces dimerization of the receptor with formation of
homodimers and heterodimers, which leads to the activation
of tyrosine kinase. The intracellular tyrosine kinase residues
then become autophosphorylated, inducing activation of
multiple signal transduction pathways. Two main intra-
cellular pathways activated by EGFR are the mitogen-
activated protein kinase (MAPK) pathway and the phos-
phatidylinositol 3-kinase- (PI3K-) protein kinase B (AKT)
pathway. These pathways lead to the activation of various
transcriptionfactorsthatthenimpactcellularresponsessuch
as proliferation, migration, diﬀerentiation, and apoptosis
[2].
Signaling through the EGFR pathway is a complex
process that requires tight regulation [2]. The ﬁrst level
of complexity is encountered at the receptor level, where2 Pathology Research International
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Figure 1: EGFR signaling pathway. Ligand binding induces dimerization and activates the EGFR. Subsequent autophosphorylation of
tyrosine residues activates downstream signaling. In the Ras-Raf-MEK-MAPK, one axis of the EGFR signaling cascade, an adaptor protein
complexcomposedofgrowthfactorreceptor-boundprotein2adapterprotein(Grb2),whichharborsatyrosinephosphate-dockingsite,and
sonofsevenless(SOS),aRasGDP/GTPexchangefactor,thenactivatestheRasGTPase.Afteractivation,Ras(i.e.,KRas)recruitsandactivates
theserineproteinRaf(i.e.,B-Raf),andsubsequentphosphorylationandactivationofMEKandthenMAPKoccurs,resultinginactivationof
transcriptionfactorsinthecellnucleus.TheRas-Raf-MAPKsignalingpathwayisthoughttocontrolcellgrowth,diﬀerentiation,andsurvival
(?apoptosis). The other axis of the EGFR signaling cascade that is important in colorectal carcinogenesis is the PI3K-AKT pathway. Once the
EFGR tyrosine residues are phosphorylated, PI3K is translocated to the cell membrane and binds to tyrosine phosphate (through its adaptor
subunitp85)whichtriggersthePI3Kcatalyticsubunitp110toproducephosphatidylinositol-3,4,5-triphosphate(PIP3).PI3Kthenpromotes
AKT activation. Activated AKT (p-AKT), present within the cytoplasm, then activates various targets that result in cell growth, proliferation,
andsurvival(parallelingtheRas-Raf-MEK-MAPKsignalingpathway).Importantly,thesetwoaxes arecloselyrelatedandhavesomeoverlap.
For example, the p110 subunit of PI3K can also be activated via interaction with Ras. Of note, phosphatase with tensin homology (PTEN)
is a phosphatase that converts PIP3 back to phosphatidylinositol (4, 5) bisphosphate (PIP2), thereby negatively regulating the PI3K-AKT
pathway.
multiple ligands are shared and lateral signaling occurs
between members of the ErbB family. Then there are positive
and negative feedback loops built into the pathways and
diﬀerential activation of transcription factors, depending
upon the cell type. When this tightly regulated system goes
awry, it can contribute to malignant transformation and
tumor progression through increased cell proliferation,
prolonged survival, angiogenesis, antiapoptosis, invasion,
and metastasis [3, 4].
3. The EGFRPathway andColorectal
Carcinogenesis(Table 1)
3.1. EGFR Protein Expression. EGFR expression (or overex-
pression), typically determined by immunohistochemistry,
has been found to be associated with tumor progression and
poor survival in various malignancies, such as carcinomas
of the head and neck [5]. However, the signiﬁcance of
EGFR protein expression is controversial in other tumors,
such as lung carcinomas [6]. Although EGFR has been
reported to be overexpressed in anywhere from 25% to
82% of colorectal cancers [4], some recent studies report
protein overexpression (deﬁned as 2+ and/or 3+ staining
or in >50% of cells) in 35 to 49% of cases [7–9]. However,
the clinical signiﬁcance of EGFR overexpression in colorectal
cancerisuncertain.Whileonestudyof249colorectalcancers
demonstrated an association of EGFR overexpression with
tumor grade (poor diﬀerentiation) (P = .014) [8], another
group found no association with grade in 134 tumors [9].
Similarly, some studies have found an association between
EGFR overexpression (deﬁned as 2+ or 3+ intensity) and
reduced survival [7, 9], while others have not [4].
Due to the known expression of EGFR in colorectal
cancer, a phase II trial of cetuximab, an anti-EGFR mon-
oclonal antibody, in patients with refractory EGFR-positivePathology Research International 3
Table 1: Components of the EGFR signaling pathway important in colorectal cancer.
Component
(gene/protein) Protein function Defect in CRC Frequency
Impact
Prognostic Predictive
(to anti-EGFR therapy)
EGFR/EGFR Transmembrane tyrosine
kinase receptor
Protein expression 25–90% Controversial No correlation
Mutation Rare Unknown Unknown
Increased copy number 0–50%∗ Uncertain Uncertain
KRas/KRas
GDP-/GTP-binding
protein; facilitates
ligand-dependent signaling
Activating mutation
(codons 12, 13, 61, 146);
leads to activation of
MAPK pathway
30–40% Controversial No response
(if KRas is mutated)
BRAF/B-Raf Serine-threonine protein
kinase downstream of KRas
Activating mutation
(V600E) 5–12%
Poor progno-
sis in MSS
tumors
No response
(if BRAF is mutated)
PIK3CA/PI3K A key signal transducer in
the PI3K-AKT pathway
Activating mutation (exons
9 and 20) 14–18%
Poor rognosis
in KRas wt
tumors
No response
(if exon 20 is mutated)
PTEN/PTEN
A protein tyrosine
phosphatase enzyme;
inactivates PI3K pathway
Loss of protein expression;
mutation; LOH 13–19%
Poor progno-
sis in KRas wt
tumors
No response
(possibly)
CRC: colorectal cancer; LOH: loss of heterozygosity; wt: wild-type.
∗L o w%f o rh i g h( >10 copies) ampliﬁcation; higher % for low number of copies (3–5 copies).
(assessed by immunohistochemistry) colorectal cancer was
undertaken [10]. The results of this trial, reported in 2004,
were promising. It was soon discovered, however, that there
was no correlation between EGFR expression in the tumor
and response to therapy [11, 12]. In the study by Chung et
al., four of 16 (25%) patients with EGFR-negative tumors
who received cetuximab-plus-irinotecan therapy achieved
a partial response with a greater than 50% reduction in
the size of measurable lesions [11]. This response rate is
nearly identical to the 23% response rate seen in a separate
cetuximab-plus-irinotecan clinical trial in EGFR-positive
patients [12]. As a result, cetuximab is now administered as
indicated without the need for EGFR testing.
The wide range of EGFR expression in colorectal cancer
reportedintheliterature,aswellastheuncertainsigniﬁcance
of EGFR expression as a prognostic indicator, may be related
to the methodology used to detect EGFR. Most studies
use immunohistochemistry to detect EGFR expression in
colorectal cancers. As demonstrated by the experience of
HER2 expression in breast cancer, immunohistochemistry is
highly dependent on the antibody clone that is used, staining
protocols, selection of scoring methods, and selection of
cutoﬀ values. Until a standard method of EGFR staining
and reporting is adopted, the signiﬁcance of EGFR protein
expression in colorectal cancer remains controversial.
3.2. EGFR Mutations, Gene Ampliﬁcation, and Copy Number.
Mutations aﬀecting the extracellular domain of EGFR,
often accompanied by gene ampliﬁcation, are frequent in
glioblastomas [13], while mutations in the tyrosine kinase
domain of EGFR, also frequently associated with increased
EGFR gene copy numbers, are clinically relevant in lung
adenocarcinoma [6, 14–16]. Unlike lung cancer and other
tumors, EGFR gene mutations are uncommon in colorectal
cancers [17, 18].
The signiﬁcance of EGFR gene ampliﬁcation/increased
EGFR copy number is more diﬃcult to summarize. Some
studies report that EGFR gene ampliﬁcation (assessed by
in situ hybridization methods) is uncommon in colorectal
cancer [19, 20]. In contrast, in recent studies on chemore-
fractory colon cancers, it appears that modest increases in
copy number (three- to ﬁvefold) are present in up to 50% of
cases [21]. It appears, however, that increased EGFR protein
expression does not always translate into increased EGFR
gene dosage [19, 21, 22]. For example, a study by Shia et al.
found that only a small fraction (17 of 124 or 14%) of EGFR-
positive (deﬁned as 1+, 2+, or 3+) colorectal carcinomas
detected by immunohistochemistry were associated with
EGFRgeneampliﬁcation(deﬁnedas>5genecopies/nucleus)
[19].
Similarly, the predictive signiﬁcance of EGFR gene
ampliﬁcation is also confusing and uncertain. One study of
47 patients with metastatic colorectal cancer treated with
a cetuximab-based regimen showed that EGFR gene copy
gain, as assessed by ﬂuorescence in situ hybridization, had
no correlation with objective response rate, disease control
rate, progression-free survival, or overall survival [23].
Conversely, another study of 173 patients with KRas wild-
type metastatic colorectal cancer treated with a cetuximab-
based regimen found that EGFR ampliﬁcation/increased
EGFR copy number, present in 17.7% of patients, was
associated with response to anti-EGFR therapy [24]. These
conﬂicting results may be related to the fact that there are no
establishedguidelinesforEGFRgeneampliﬁcation.Butsince
there are no guidelines, testing for EGFR gene ampliﬁcation
in colorectal cancer is not routinely performed.4 Pathology Research International
In addition to molecular alterations of the EGFR gene,
activation of EGFR downstream eﬀectors can lead to tumor
formation/progression. Speciﬁc alterations can impact prog-
nosis and predict response to anti-EGFR therapy.
3.3. KRas Mutations. The KRas proto-oncogene encodes a
21-kDa guanosine 5 -triphosphate- (GTP-) binding protein
at the beginning of the MAPK signaling pathway. Somatic
KRas mutations are found in many cancers, including 30%–
40% of colorectal cancers, and are an early event in carcino-
genesis [25–29]. KRas mutations, most commonly codon
12/13 missense mutations, lead to constitutive activation
of the KRas protein by abrogating GTPase activity. These
mutations result in unregulated downstream signaling that
will not be blocked by antibodies that target the EGFR
receptor.
The prognostic signiﬁcance of KRas mutations is contro-
versial. KRas mutation status is associated with shorter sur-
vival in some studies [28, 30–32], but not others [29, 32, 33].
The results of one study, which showed increased mortality
with codon 13 G-A mutations but not with KRas mutations
in general, suggest that prognosis may be related to speciﬁc
mutations in the KRas gene [28]. Although not predictive
of outcome with standard chemotherapy, KRas mutation
status is a strong predictive marker of resistance to EGFR-
targeted therapy in patients with metastatic colorectal cancer
(i.e., KRas mutations predict a lack of response to anti-EGFR
monoclonal antibodies cetuximab and panitumumab) [34–
39]; this topic is discussed in detail in another paper in
this series, “Impact of KRas mutations on management of
colorectal cancer” by Sullivan and Kozuch.
3.4. BRAF Mutations. The BRAF gene encodes a serine-
threonine protein kinase that is downstream of KRas
in the MAPK signaling pathway. BRAF mutations occur
in 5–22% of all colorectal cancers [40, 41]. When
separated by microsatellite instability status, BRAF muta-
tions are present in 40–52% of colorectal cancers that
arise through the microsatellite instability pathway (MSI)
pathway (microsatellite unstable tumors) [41–44], but only
5% of cancers are microsatellite stable [42]. The most
frequently reported BRAF mutation is a valine-to-glutamic
acid amino acid (V600E) substitution [45]. BRAF mutations
are mutually exclusive with KRas mutations [41].
Unlike KRas mutations, BRAF mutations do have an
impact on prognosis and survival. In some studies, the
eﬀect is dependent upon the microsatellite status of the
colorectal cancer. Patients with a BRAF mutation in a
microsatellite-stable colon cancer have signiﬁcantly poorer
survival than those without the mutation, but the BRAF
status does not aﬀect survival of patients with microsatellite-
unstable tumors [29, 42]. In patients with metastatic KRas
wild type tumors, BRAF mutations have been associated
with shorter progression-free and shorter overall survival
[24]. BRAF status also predicts response to anti-EGFR
therapy. Of metastatic colorectal cancers that are found to
be KRas wild type at codons 12/13, 5% to 15% can harbor
BRAF mutations and show resistance to anti-EGFR therapy
[46, 47]. The predictive role of BRAF mutations is further
covered in another article in this series, “Impact of KRas
mutations on management of colorectal cancer.”
3.5. The PI3K Pathway-PIK3CA Mutations and Expression of
PTEN and p-AKT. T h eP I 3 K - A K Tp a t h w a yc a nb ed e r e g -
ulated by activating mutations in the PIK3CA gene (p110
subunit), by inactivation (often by epigenetic mechanisms)
of the phosphatase and tensin homolog (PTEN)g e n e ,o r
by activation of AKT [1, 48]. The PIK3CA gene encodes
phosphatidylinositol3-kinase(PI3K),akeysignaltransducer
in the PI3K-AKT pathway. Mutations in PIK3CA occur in
14% to 18% of colon cancers, and most mutations involve
hotspots on exons 9 and 20 [47, 49]. Interestingly, there
is a strong association between PIK3CA exon 9 mutations
and KRas mutations [47]. As a prognostic marker, PIK3CA
mutations are associated with shorter cancer-speciﬁc sur-
vival, but this eﬀect may be limited to patients with KRas
wild-type tumors [49]. Brieﬂy, as a predictive marker, only
PIK3CA exon 20 mutations appear to be associated with
worse outcome after cetuximab [47].
The PTEN gene encodes a protein tyrosine phos-
phatase enzyme (PTEN) that dephosphorylates phosphat-
idylinositol-3,4,5 triphosphate (PIP3) and thereby inhibits
PI3K function [1]. Loss of PTEN results in constitutive
activation of the PI3K-AKT pathway. PTEN mutations and
loss of heterozygosity (LOH) of the PTEN locus have been
reported in 13%–18% and 17%–19% of colon cancers,
respectively [50, 51]. It appears that loss of PTEN has
prognostic value. Loss of PTEN protein expression (assessed
by IHC) is associated with shorter overall survival in patients
with KRas wild-type tumors [24]. It appears that there is
an association with PTEN mutations/LOH with MSI status,
but the current published results are conﬂicting [50, 51].
PTEN protein inactivation may also be a negative predictor
of response to anti-EGFR therapy [22, 52].
AKT is a major downstream eﬀector of PI3K. A recent
study by Baba et al. examined the role of activated (phos-
phorylated) AKT expression in a large cohort of colorectal
cancers [48]. They demonstrated that p-AKT expression
is associated with early stage disease and good prognosis.
They also showed that p-AKT expression is associated with
PIK3CA mutation, as expected from their relationship in
the EGFR pathway, but that the prognostic eﬀect of p-
AKT expression was independent of PIK3CA mutation. It
is possible that p-AKT expression could serve as positive
prognostic marker in patients with colorectal cancer.
In summary, the EGFR signaling pathway is a complex
and tightly regulated process that is involved in growth,
proliferation, and survival of normal cells. When this
system goes awry and unchecked, it can lead to growth,
proliferation, survival, and metastasis of neoplastic cells.
Alterations within the EGFR signaling cascade, such as gene
mutations, gene ampliﬁcation, and protein overexpression,
have been shown to contribute to colorectal carcinogenesis.
Some alterations also portend a poor prognosis in patients
with colorectal cancer. Due to the complex interaction of
EGFR and its downstream regulators, the study of individualPathology Research International 5
components of this pathway often yields conﬂicting results,
as noted in this paper. Hence, there are still many questions
that need to be answered before we can fully understand
the impact of the EGFR signaling pathway on colorectal
carcinogenesis and the prognosis of patients with colorectal
cancer.
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